Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nisoldipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 10/20 | 1.00 |
| ▸ | CACNA1F known ✓ | O60840 | 9/20 | 1.00 |
| ▸ | CACNA1D known ✓ | Q01668 | 9/20 | 1.00 |
| ▸ | CACNA1S known ✓ | Q13698 | 9/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | SCN1A | P35498 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 2/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 2/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nisoldipine SCHEMBL1172989 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL29420725 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL19348996 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL39780 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL919020 | 0.99 | CACNA1C (0.98) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL27608147 | 0.99 | CACNA1C (0.98) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL3855961 | 0.99 | CACNA1C (0.98) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| SCHEMBL4608536 | 0.96 | CACNA1D (0.92) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| SCHEMBL9765770 | 0.93 | CACNA1C (0.86) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| SCHEMBL7432246 | 0.92 | CACNA1C (0.84) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 20848 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107071-A1 | COMBINATION THERAPY | Retension Pharmaceuticals, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4724060-A1 | FORMULATIONS AND METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS | HB Biotech, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| EP-4683634-A1 | TREATMENT OF SCLERODERMA | Aisa Pharma, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| US-4703038-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1987-10-27 | — | — | US | claimed |
| EP-0237506-A1 | Pharmaceutical composition | LEJUS MEDICAL AKTIEBOLAG (SE) | 1987-09-16 | — | — | EP | claimed |
| US-4693892-A | LIGHTFAST | BAYER AKTIENGESELLSCHAFT (DE) | 1987-09-15 | — | — | US | claimed |
| EP-0221382-A1 | Method and compositions for the treatment of tumors comprising a calcium channel blocker compound of the dihydropyridine class and a platinum coordination compound | THE BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) | 1987-05-13 | — | — | EP | claimed |
| CN-85102334-A | The method for preparing dihydropyridine preparation | — | 1987-01-24 | — | — | CN | claimed |
| EP-0204951-A2 | Use of calcium channel blockers in the production of compositions for withdrawal symptoms | MILES INC. (US) | 1986-12-17 | — | — | EP | claimed |
| CN-85109017-A | The preparation technology of different dihydropyridine mixture and the purposes aspect medical thereof | — | 1986-08-27 | — | — | CN | claimed |
| US-4582840-A | SALURETICS; VASODILATION; HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-04-15 | — | — | US | claimed |
| US-4537898-A | WITH POLYOXYETHYLENE GLYCOL DERIVATIVES AS SOLUBILIZERS | BAYER AKTIENGESELLSCHAFT (DE) | 1985-08-27 | — | — | US | claimed |
| US-4154839-A | INCREASING CORONARY PERFUSION | BAYER AKTIENGESELLSCHAFT (DE) | 1979-05-15 | — | — | US | claimed |